Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.
Our Solutions

Solutions the moment you need them

Our commitment is to provide high-quality solutions through the integration of technology, support, and expert knowledge — when it matters most. Explore our portfolio of therapies, designed to help manage critical imbalances and support patient care across diverse clinical fields.

Restore balance to support clinical management

*Not available in the US

 

Empowering independent hemoadsorption therapy

*Not available in the US

 

Supporting ex vivo organ perfusion through adsorptive removal of inflammatory mediators

*Not available in the US

 

CytoSorb technology designed for veterinary critical-care applications

*Available only in the US

 

Additional Information

  • Jansen et al., Crit Care 2023; 27(1):117
  • Diab et al., Circ 2022; 145(13):959-968
  • Scharf et al., Sci Rep 2021; 11(1);10190
  • Albrecht et al., Blood Purif 2024; 53(2):88-95
  • Hassan et al., JTCVS Open 2023; 15:190-196
  • Chen J et al, Regenerative Biomaterials 2017; 4(1):31-37
  • Waalders et al., Crit Care Med 2024; 52(4):e152-e153
  • Bernardi et al., Crit Care 2016; 20(1):96
  • Poli et al., Crit Care 2019; 23:108
  • Gleason et al., Sem Thorac Cardiovasc Surg 2019; 31(4):783-793
  • David et al., J Int Care 2017; 5:12
  • Kogelmann et al., J Clin Med 2024; 13(1):294
  • Soltesz et al., J Clin Med 2022; 11(12):6517
  • Rugg C et al., Biomedicines 2020; 8(12):539
  • Szigetvary et al., Biomed 2023; 11811):3068
  • Riva et al., J Artif Orgs 2023; epub
  • Grafe et al., Ren Fail 2023; 45(2):2259231
  • Hassan et al., Ann Thor Cardiovasc Surg 2022; 28(3):186-192
  • Hassan et al., Ann Thorac Surg 2019; 108(1):45-51

CytoSorb 300 IFU 03/2023 – Indications: CytoSorb is indicated for use in conditions where elevated levels of cytokines and/or bilirubin and/or myoglobin exist. CytoSorb is indicated for use intraoperatively during cardio-pulmonary bypass surgery for the removal of P2Y12-Inhibitor Ticagrelor and/or Factor Xa-Inhibitor Rivaroxaban. Results from current studies suggest that CytoSorb may be administered for up to 7 consecutive days. Maximum Treatment Time per Device: 24 Hours

CytoSorbents

Voices around the world

world map
Cardiovascular
Prof. Dr. Markus Krane
Munich, Germany

Post-operative bleeding and related post-operative blood transfusion, that are usually necessary, are reduced. And that’s a better outcome for the patient.

Critical Care
Dr. Guadalupe Castillo
Panama City, Panama

CytoSorb definetely gives us the opportunity to prevent the patient from developing complications or facing a more serious situation, which could lead to death.

Cardiovascular
Prof. em. Heinz Jakob
Essen, Germany

Listen to Dr. Heinz Jakob talk about his experiences with CytoSorb Therapy.